Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myeloproliferative Disorders 3Solid Tumor 1Neoplasms 1Leukemia 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cytarabine 11Cyclophosphamide 10Filgrastim 9Etoposide 8fludarabine phosphate 6Vorinostat 6Tacrolimus 6Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Dasatinib 6Carboplatin 5tipifarnib 4sargramostim 4Topotecan 4Sirolimus 4Bortezomib 4tanespimycin 3fludarabine 3alvocidib 3Whole-Body Irradiation 3Sorafenib 3Flow Cytometry 3Doxorubicin 3Decitabine 3Busulfan 3Antilymphocyte Serum 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3laromustine 2entinostat 2bryostatin 1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Blast Crisis × fedratinib × Clear all
NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Columbia University

Phase 1 Terminated
2 enrolled
Myeloid

Blast Crisis, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡